The Hype Market Review (W/E 8/9): The Dreams Rallied. The Earnings Didn't.

Pre-revenue neoclouds, quantum and space names jumped 20–30% on backlogs and Washington cheques, while Reddit's 61% growth, Roblox's 36% and Alnylam's first $1B drug all got sold.

The Tape

The speculative top of the market threw a party, and the profitable bottom got handed the bill. AI Neoclouds ran +30.5% and Quantum +23.1% — one on a backlog CoreWeave hasn't turned into a profit, the other on IonQ revenue growth that was mostly a $1.06B accounting mark — while Alnylam crossed $1B in quarterly sales of a single drug and fell 25%, Roblox grew revenue 36% and shed $9B in value, and Universal Music grew 5.3% and lost a quarter of its market cap. The dreams got bid; the earnings got sold. This week, a real number was a liability.

Reversal of the week AI Neoclouds swung from −12.5% to +30.5%.

The movers

• AI Neoclouds +30.5% — CoreWeave, the rent-a-GPU landlord, opened its first Asian data center and led at +40% on a $98.8B order backlog it has yet to convert into cash; last quarter's net loss widened to $740M. CRWV carried 57% was −12.5% ▲43.0
• Quantum +23.1% — IonQ's revenue grew 287%, but its $804.6M "profit" was really a $1.06B non-cash warrant mark; Arqit, the quantum-encryption firm, added 39% on no disclosed news whatsoever. broad · 6/6 names was −0.4% ▲23.5
• Space +22.7% — the small fry strapped themselves to SpaceX and lit the fuse: Redwire, a space-hardware maker, booked a pharma mission aboard a Starfall craft and shot up 52%, while SpaceX, the actual $7.8B-revenue business, managed 2%. broad · 10/10 names was −6.0% ▲28.7
• Rare Earths & Critical Minerals +20.6% — Washington turned dirt into a trade with a White House minerals summit and a Lockheed scandium deal; USA Rare Earth, a still-tiny miner, jumped 33% on $5.7M of revenue against a $68.1M loss. broad · 8/8 names was −5.5% ▲26.1
• AI Power +18.9% — the one AI rally that came with receipts: Coherent, an optical-components maker feeding data centers, swung to a $191M profit as datacenter revenue leapt to $1.36B, and led the group at +50%. broad · 10/12 names was −7.5% ▲26.4
• Robotics +16.0% — lidar maker Ouster grew revenue to $54.6M and jumped 46%, yet the only name that actually posted a profit — warehouse-robot firm Symbotic, at $55M — was the only one to fall. broad · 8/11 names was +1.6% ▲14.4
• Hydrogen & Fuel Cells +15.8% — Bloom Energy, which makes on-site fuel-cell power, nearly tripled revenue to $1.065B and swung to a $182M operating profit; the rest rode its coattails while Plug Power's loss widened to $246M. mixed · 2/4 was −4.7% ▲20.5
• Batteries & Solid-State +15.3% — how much did fundamentals matter here? Solid Power reported negative $1M of revenue after reversing an SK On payment, and still gained 9%; Amprius, which posted a record $34M, led at +33%. broad · 7/8 names was −3.8% ▲19.1
• eVTOL & Flying Cars +13.1% — air-taxi frontrunner Joby raised guidance and led at +24%, sitting on $2.26B of cash against half-year revenue of $62.9M. The runway is long; the revenue is less so. broad · 6/6 names was −5.8% ▲18.9
• Defense + Drones +12.8% — Kratos, a drone and missile-systems maker, grew revenue 30.5%, bought two companies and raised its 2026 outlook to lead at +31%; a geopolitics bid under the smaller drone names did the rest. broad · 8/9 names was −5.0% ▲17.8
• Nuclear Energy +12.6% — enthusiasm this pure needs no earnings: NuScale, a small-modular-reactor developer, watched revenue collapse 97% to $640K and its loss widen to $96.7M, and rose a quarter for the trouble. broad · 12/14 names was −6.1% ▲18.7
• AI Drug Discovery +9.7% — Absci, an AI antibody designer, popped 20% on positive hair-loss trial data and a $100M Lilly-backed raise, while modeling-software firm Simulations Plus sat flat under an accounting investigation. SDGR carried 54% was +1.1% ▲8.6

The Stories

The GPU landlords rented out the whole market

The cleanest way to bet on AI this week was to own the building the chips sit in. CoreWeave, which rents Nvidia GPUs by the hour, opened its first Asia-Pacific data center and climbed 40% on a $98.8B pile of booked-but-undelivered orders.

It is worth noting what that backlog hasn't done yet: earn money. CoreWeave's Q1 net loss nearly doubled to $740M, and analysts expect its coming Q2 to show a decline. The market bought the backlog anyway.

The picks-and-shovels names, at least, brought numbers. Coherent, an optical-components maker, swung to a $191M profit as its datacenter revenue leapt to $1.36B; Astera Labs, which builds AI connectivity chips, more than doubled revenue to $392M.

And the bitcoin miners are quietly becoming AI landlords. Core Scientific grew colocation revenue to $136.7M from $10.6M a year ago and reserved 2.5 gigawatts for AMD; TeraWulf signed Anthropic, maker of the Claude chatbot, to a $19B Kentucky data-center lease. Now there's a business.

Washington made a market out of dirt

The rare-earth rally didn't come from China or commodity prices. It came from a White House guest list. President Trump hosted mining CEOs as his administration hunts for minerals to feed defense supply chains, and eight names lit up.

MP Materials, America's flagship rare-earth miner, doubled revenue to $108.5M and won a Pentagon guarantee of at least $140M in annual EBITDA from a facility that isn't built. NioCorp, a Nebraska developer, signed a scandium-supply memorandum with Lockheed Martin.

In fairness, the strategic case is real — the West genuinely lacks these inputs. But the tape wasn't pricing production; it was pricing proximity to a federal cheque. USA Rare Earth rose 33% on $5.7M of revenue and a $68.1M loss.

The same government-largesse trade ran through nuclear, where NuScale watched its revenue collapse 97% to $640K, widened its loss to $96.7M, and rose a quarter of its value anyway. The question is whether the cheques survive contact with the next budget.

A billion-dollar drug, a 25% haircut

The other half of the market spent the week being punished for delivering. Alnylam, a gene-silencing drugmaker, crossed $1B in quarterly sales of a single drug, AMVUTTRA — then fell 25% when it trimmed guidance as pent-up demand "normalized."

Roblox, the kids' gaming platform, grew revenue 36% to $1.47B and lost 28%; one product change, per the trade, "wiped out $9 billion." Reddit grew revenue 61% to $804.9M and tripled its profit, then dropped 15% on a data-scraping lawsuit and user backlash.

Music was a clean sweep of the same disease. Universal Music Group grew revenue 5.3% and shed a quarter of its value — a drop so unexplained the trade press openly asked why. Spotify passed its 300-millionth premium subscriber and fell 9%.

Even Rush Street, an online-betting operator, grew revenue 46% and doubled operating income into an 18% loss. Growth was everywhere. It just wasn't the currency anyone wanted to be paid in.

The obesity trade split on the middleman, not the molecule

The weight-loss sector barely moved as a whole, +2%, but underneath it the two ends pulled hard against each other — and the fight was about distribution, not drugs.

Novo Nordisk, maker of Wegovy, cut prices to claw back share it's losing and added an eye-disease side-effect warning to the label. It fell 11%.

Hims & Hers, the telehealth seller, jumped 19% for doing the opposite: it added Eli Lilly's rival GLP-1 treatments to its lineup, with its CEO comparing the move to "Netflix's early days." Lilly's Zepbound, for its part, booked $4.928B in the quarter.

The lesson isn't about semaglutide. When the company that makes the drug torches its own pricing while the company that merely ships it soars, the money has decided the shelf is worth more than the lab.

The week, visualized